Xvivo Perfusion (Q4 Review): Setting up for a strong 2026 - Redeye

Redeye returns with a more in-depth take on Xvivo’s Q4 report. We find the report supportive of our take on the case, with returning strong sales development and solid profitability that should re-ignite interest for 2026, which holds several inflexion points.

Länk till analysen i sin helhet: https://www.redeye.se/research/1146170/xvivo-perfusion-q4-review-setting-up-for-a-strong-2026?utm_source=finwire&utm_medium=RSS